KalVista Pharmaceuticals (KALV) Earnings Date, Estimates & Call Transcripts $15.39 -0.62 (-3.87%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$15.30 -0.10 (-0.62%) As of 07/18/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KalVista Pharmaceuticals Earnings Summary KalVista Pharmaceuticals released Q4 2025 earnings on July 10, 2025, reporting an EPS of -$3.69, which missed the consensus estimate of -$0.83 by $2.86. With a trailing EPS of -$3.69, KalVista Pharmaceuticals' earnings are expected to grow next year, from ($3.56) to ($2.90) per share. Upcoming Q1 Earnings DateSep. 4Before Market OpensEstimatedConsensus EPS (Jul. 10) -$0.83 Actual EPS (Jul. 10) -$3.69 Missed By -$2.86 Q4 2025 Earnings ResourcesQ4 2025 Earnings Report Press Release (8-K) Annual Report (10-K)KALV Upcoming EarningsKalVista Pharmaceuticals' next earnings date is estimated for Thursday, September 4, 2025, based on past reporting schedules. Powered by Get KalVista Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataKALV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. KalVista Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.90-$0.72-$0.81Q2 20252-$0.91-$0.71-$0.81Q3 20252-$0.89$0.81-$0.04Q4 20252-$0.77-$0.35-$0.56 FY 2025 8 -$3.47 -$0.97 -$2.22 Q1 20261-$0.72-$0.72-$0.72Q2 20261-$0.60-$0.60-$0.60Q3 20261-$0.54-$0.54-$0.54Q4 20261-$0.42-$0.42-$0.42 KalVista Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 9/4/2025(Estimated)--------7/10/2025Q4 2025-$0.83-$3.69 -$2.86-$0.99$4.20M-12/5/2024Q2 2025-$0.92-$0.91+$0.01-$0.91--9/5/2024Q1 2025-$0.91-$0.87+$0.04-$0.87--7/11/2024Q4 2024-$0.73-$1.02 -$0.29-$1.02--3/11/2024Q3 2024-$0.75-$0.84 -$0.09-$0.84--12/7/2023Q2 2024-$0.76-$0.80 -$0.04-$0.80--9/7/2023Q1 2024-$0.86-$0.74+$0.12-$0.74-- KalVista Pharmaceuticals Earnings - Frequently Asked Questions When is KalVista Pharmaceuticals' earnings date? KalVista Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, September 4th, 2025 based off last year's report dates. Learn more on KALV's earnings history. Did KalVista Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, KalVista Pharmaceuticals (NASDAQ:KALV) missed the analysts' consensus estimate of ($0.83) by $2.86 with a reported earnings per share (EPS) of ($3.69). Learn more on analysts' earnings estimate vs. KALV's actual earnings. How much profit does KalVista Pharmaceuticals generate each year? KalVista Pharmaceuticals (NASDAQ:KALV) has a recorded net income of -$183.44 million. KALV has generated -$3.69 earnings per share over the last four quarters. What is KalVista Pharmaceuticals' EPS forecast for next year? KalVista Pharmaceuticals' earnings are expected to grow from ($3.56) per share to ($2.90) per share in the next year. More Earnings Resources from MarketBeat Related Companies KYMR Earnings Results RARE Earnings Results ALVO Earnings Results AMRX Earnings Results MIRM Earnings Results CPRX Earnings Results ARWR Earnings Results IBRX Earnings Results OGN Earnings Results APLS Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report This page (NASDAQ:KALV) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
